explore -WSS

explore

author：focus 2025-10-03 00:07:26 - browse：75644

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

WSS

The FDA must approve intranasal treatments for anaphylaxis

STAT Readout Newsletter: Biotech news today

J&J to buy cancer drug developer Ambrx Biopharma

3 medical device trends to watch in 2024

Is there really a nursing shortage in the U.S.?

STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

explore

leisure time

The high cost of giving birth even with insurance

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

How one medical school became remarkably diverse

J&J lung cancer data amount to new salvo against AstraZeneca

Sports medicine is finally prioritizing gender equality

Readout LOUD podcast: Live from the 2023 STAT Summit

In Memoriam: Notable people who died in 2023

Chronically ill young patients struggle to find fertility info

The cancer drug shortage isn’t new — and neither are the solutions

How a scoliosis diagnosis changed the life of one young dancer

knowledge

Results on Novartis prostate cancer therapy could expand its use

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Cassava Sciences’ Alzheimer’s clinical trials should be halted

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

How AI can help patients find reliable information about doctors

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

focus

knowledge

Wikipedia